

35th Annual
J.P. Morgan Healthcare Conference



A Taiwanese Leading Biotech Since 1997

Wayne Tan
Chairman Advisor

Group Profile

- **1997** Established with **4** listed in Taiwan
- **750** million USD Investment
- **12** New Drugs Pipeline
- **4** R&D Centers
- **2** GMP Manufacturing Plants in Taiwan
- **1** GMP Manufacturing Plant in China
- **80** In-House Scientists + **5** Research institutions

Pipeline

Pre-Clinical	Phase 1	Phase 2	Phase 3	Approved
+ FB704A Anti-IL-6, Antibody + FB121 Anti-CD4, Antibody	+ OB318 HCC + MB110 HCV-NS5B, Small Molecule + SNP630 NASH, Small Molecule + SNP810 Hepatotoxicity Free Acetaminophen + FB317 Anti-IgE, Antibody	+ FB825 Anti-CemX, Antibody	+ ON101 Diabetic Foot Ulcer + MB6 Colon Cancer	+ MS20 Oncology + Herbiron Anemia

2 Approved Drugs and 10 Programs on Pre-clinical & Clinical Stage




FB825

Treatment for IgE-Related Allergic Diseases

A Novel Long-acting Anti-CεmX Antibody


Mechanism of Action




Only Microbio & Roche have the CεmX domain patent

FB825 Phase I Study Result in USA

IgE suppression up to **140** days



Fast Reduction in High IgE



Long-acting Effect

Excellent Pharmaco-economic Benefit

Product	Target	Status	Dosing
FB825	mIgE	Phase I	12 w
Omalizumab	IgE	Approved	2~4 w
Ligelizumab	IgE	Phase II	2~4 w
Dupilumab	IL-4Ra	Phase III	1~4 w
Mepolizumab	IL5	Approved	4 w
Lebrikizumab	IL13	Phase III	4 w

3 months per dose

FB825 Indications for Allergic Diseases

Atopic Dermatitis

Allergic Asthma

Severe Allergic Rhinitis

Scatter plot showing the relationship between the Severity of AD (IGA Score) and IgE Concentration (IU/ml).

The Y-axis represents IgE Concentration (IU/ml) on a logarithmic scale, ranging from 10 to 100,000. The X-axis represents the Severity of AD (IGA Score), ranging from 1 to 5.

Legend:

- Average IgE Level (Red horizontal line)
- Individual IgE Level (Blue diamonds)

A horizontal dashed line indicates the average IgE level at 1500 IU/ml. A blue oval highlights the data points for IGA scores 3, 4, and 5, which are above the average level. A large blue arrow points down to the oval, and a vertical double-headed arrow on the right indicates the range from 40% to 60% of the average level.

Severity of AD (IGA Score)	Individual IgE Level (IU/ml)
1	80, 150, 200, 300, 900
2	90, 250, 400, 600, 1100, 5000
3	120, 250, 400, 500, 550, 600
4	600, 1200, 4000, 5000, 6000, 7000, 15000, 50000
5	4000, 6000, 8000, 9000, 10000, 15000, 20000, 25000

Only solution for High IgE Patients

Allergic Asthma

Comparison of **FB825** and Omalizumab

	FB825	Omalizumab
Dosing frequency	12 weeks or more	2-4 weeks
IgE Limitation	No limitation	IgE < 1500IU/ml

FB825

Superior with less dosing frequency

No limitation in patient IgE level

Allergic Asthma

Comparison of **FB825** and Quilizumab

	FB825	Quilizumab
Binding Epitope	G L A G G S A Q S Q R A P D R	A Q S Q R A P D R V L C H S G
Half Life	19-26 Days	20 Days
IgE Reduction (by day 85)	40-50%	23-28%

FB825


More potent comparing with Quilizumab

FB825 Market Opportunity

- A better option for existing market of allergic diseases
- Fulfill medical needs of high IgE patients
- Solution for seasonal allergy

Global & Immediate Opportunities

FB825 Development Plan




Looking for Co-Development Partner

ON101

Treatment for Diabetic Foot Ulcers


60% Patients Complete Healing in **16** Weeks

Mechanism of Action



ON101 is a Creamy Drug. Easy Application and Storage

ON101 Phase III Clinical Trial Case Study



> 11cm² complete healing in 14 weeks

ON101 Phase III Clinical Trial Case Study

Area: 7.93 cm²



Area: 3.17 cm²



Area: 2.13 cm²



Complete Healing



Week 0

Week 2


Week 4

Week 8

8cm² (approx.) complete healing in 8 weeks


ON101 Wound Complete Healing Rates

► mITT Group




Difference = 30.5% ($p < 0.001$)

► Plantar Ulcers Group



Difference = 39.5% ($p = 0.002$)


► Large Wound Size (> 5 cm²) Group



Difference = 51.2% ($p = 0.002$)


Only Solution Over 60% Complete Healing Rates

ON101 Pharmacokinetic Study



Safe to use in chronic DFU

ON101 Development Plan (Estimated)



Looking for in-Licensing Partners

MS20

**Potent Postbiotics from
Symbiotic Anaerobic Fermentation**

New Indications Development

MS20 Gut Postbiotics

**IMMUNE
CHECKPOINT
MODULATOR**


4X anti-PD1 booster

**SEPSIS
TREATMENT**

90% survival rate



**CHEMOTHERAPY
COMBINED
TREATMENT**

New drug approved
by TFDA since 2012



Immune Checkpoint Modulator

Combination Therapy of MS-20 & Anti-PD-1




Improve Survival Rate and Reduce Tumor Size



Sepsis Treatment


CLP-Induced Sepsis Animal Model




90% Survival Rate on Sepsis

MS20 for CACHEXIA


Reduce Fatigue



Improve Appetite



Improve Physical Function



Immune-restoration For Chemotherapy Cancer Patients

MS20 Opportunity



1. Immune Checkpoint Modulator

2. Treatment of Sepsis

Looking for Co-Development Partners



**MICROBIO
GROUP**

Key movement from 2017

FB825 Welcome Co-Development Partner
IgE-Allergic Diseases

ON101 Welcome In- Licensing Partner
Diabetic Foot Ulcers

MS20 Welcome Co-Development Partner
Immune-Restoration

Contact

Wayne Tan
MBG_BD@microbio.com.tw